Robbins Farley’s Cardlytics CDLX Stock Holding History

Robbins Farley’s Portfolio CDLX Stock Details CDLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-10	Closed	-$14K	–	173
2020 Q4	$14K	Buy	+10	New	+$10.7K	0.01%	68

Other funds holding CDLX

CIP

CAS Investment Partners Westport, Connecticut $1.75B AUM 41.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ACM

Alua Capital Management New York $1.13B AUM 8.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

KGAMU

KPS Global Asset Management (UK) London, United Kingdom $619M AUM 27.68% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Robbins Farley's CDLX Position: Q1 2021 in Review

Robbins Farley sold out of Cardlytics (CDLX) in Q1 2021, closing a stake of 10 shares — an estimated $14K sold.

Robbins Farley first reported a position in CDLX in Q4 2020 and held it in 1 quarter. The position peaked at $14K in Q4 2020. 204 funds tracked by Wall St. Rank hold CDLX as of Q1 2021.

Robbins Farley reported no remaining Cardlytics position as of Q1 2021 after selling out during the quarter.
Robbins Farley sold 10 Cardlytics shares in Q1 2021, an estimated $14K.
Robbins Farley first reported a position in Cardlytics in Q4 2020 and held it in 1 quarter.
Robbins Farley's Cardlytics position peaked at $14K in Q4 2020.
204 funds tracked by Wall St. Rank held Cardlytics as of Q1 2021.

Based on Robbins Farley's 13F filing for Q1 2021, filed 13 May 2021.